Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics Inc demonstrates a positive outlook due to its disciplined expense management amid ongoing clinical and regulatory activities that support the advancement of its therapeutic programs. The company's dual-track strategy focusing on supportive oncology and metabolic disease is reinforced by progress on IND-enabling activities in joint venture programs, which may unlock additional incremental value. Furthermore, encouraging clinical data, with over 65% of participants reporting reductions in pain and pruritus, highlights the potential effectiveness of its treatments, thereby strengthening its multi-program strategy towards achieving key regulatory milestones.

Hoth Therapeutics reported a net loss of approximately $4.11 million for the quarter, translating to a loss of $(0.30) per share, demonstrating ongoing financial challenges. In the second quarter of 2025, the company generated no revenues, while total operating expenses decreased to $2.2 million from $3.4 million in the prior quarter, highlighting an ongoing lack of substantial revenue generation. The continuous net losses and absence of revenue raise concerns regarding the company's ability to achieve financial stability and sustain its operations moving forward.